Pulmokine Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Pulmokine General Information

Description

Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 7 University Place
  • Room B127
  • Rensselaer, NY 12144
  • United States
+1 (518) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmokine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 000 Completed Generating Revenue
5. Grant 01-Jan-2017 00000 000 Completed Generating Revenue
4. Grant 01-Jan-2016 00.000 000 Completed Generating Revenue
3. Seed Round 04-Mar-2015 000 000 Completed Generating Revenue
2. Debt - General 01-Oct-2014 Completed Generating Revenue
1. Grant 01-Jan-2014 $1.5M Completed Generating Revenue
To view Pulmokine’s complete valuation and funding history, request access »

Pulmokine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders.
Biotechnology
Rensselaer, NY
000
000000 - 000 000

000000

ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000000000000
Philadelphia, PA
00 As of 0000
000000&0

0000 0

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000 000000000
Austin, TX
00 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pulmokine Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spirovant Sciences Formerly PE-Backed Philadelphia, PA 00 000000&0
Lung Therapeutics Formerly VC-backed Austin, TX 00 000.00 000000&0 000.00
Galapagos (Biotechnology) Formerly VC-backed Mechelen, Belgium 000 00.000 000000000 00.000
Artizan Biosciences Venture Capital-Backed New Haven, CT 00 000.00 0000000000 0 000.00
Moerae Matrix Formerly VC-backed Morristown, NJ 0 000.00 00000000000 000.00
You’re viewing 5 of 30 competitors. Get the full list »

Pulmokine Patents

Pulmokine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210038510-A1 Formulations of kinase inhibitors and prostanoids Pending 08-Feb-2018 000000000 0
US-20200261448-A1 Combination therapy for treating pulmonary hypertension Active 27-Oct-2016 0000000000
US-20180117039-A1 Combination therapy for treating pulmonary hypertension Active 27-Oct-2016 0000000000
CA-3041679-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 0000000000
EP-3532063-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 A61K31/497
To view Pulmokine’s complete patent history, request access »

Pulmokine Executive Team (5)

Name Title Board Seat Contact Info
Lawrence Zisman Chief Executive Officer
Rubin Tuder MD Executive
Ron Wolff Ph.D Vice President of Regulatory Affairs and Toxicology
Aaron Waxman MD Member of Scientific Advisory Board
You’re viewing 4 of 5 executive team members. Get the full list »

Pulmokine Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Heart, Lung, and Blood Institute Government 000 0000 000000 0
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
To view Pulmokine’s complete investors history, request access »

Pulmokine FAQs

  • When was Pulmokine founded?

    Pulmokine was founded in 2007.

  • Who is the CEO of Pulmokine?

    Lawrence Zisman is the CEO of Pulmokine.

  • Where is Pulmokine headquartered?

    Pulmokine is headquartered in Rensselaer, NY.

  • What industry is Pulmokine in?

    Pulmokine’s primary industry is Biotechnology.

  • Is Pulmokine a private or public company?

    Pulmokine is a Private company.

  • What is Pulmokine’s current revenue?

    The current revenue for Pulmokine is 00000.

  • How much funding has Pulmokine raised over time?

    Pulmokine has raised $1M.

  • Who are Pulmokine’s investors?

    National Heart, Lung, and Blood Institute and National Institute Of Allergy and Infectious Diseases have invested in Pulmokine.

  • Who are Pulmokine’s competitors?

    Spirovant Sciences, Lung Therapeutics, Galapagos (Biotechnology), Artizan Biosciences, and Moerae Matrix are some of the 30 competitors of Pulmokine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »